Eli Lilly and Company - Research and Development

Eli Lilly and Company's Fiscal Year is From January To December - All Figures are in USD, Billions.

The item "Research-and-Development" stands at 13.21 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value at least since 03/31/2012, the period currently displayed.

Eli Lilly and Company's third quarter result of 4.12 Billion USD for the item "Research and Development" represents an increase of 23.54 percent compared to it's second quarter result.

Also, Eli Lilly and Company's third quarter result of 4.12 Billion USD for the item "Research and Development" represents an increase of 50.74 percent compared to it's third quarter result of last year.

Looking again at the trailing twelve months series (TTM), Eli Lilly and Company's third quarter result of 13.21 Billion USD for the item "Research and Development" represents an increase of 11.73 percent compared to it's second quarter result.


Regarding the One-Year-Change of the series, the current value constitutes an increase of 25.48 percent compared to the value the year prior.
The 1 year change in percent is 25.48.
The 3 year change in percent is 84.70.
The 5 year change in percent is 126.69.
The 10 year change in percent is 191.19.

The Serie's long term average value is 6.44 Billion United States Dollars. It's latest available value, on 09/30/2025, is 105.13 percent higher, compared to it's long term average value.
The Serie's change in percent from it's minimum value, on 09/30/2015, to it's latest available value, on 09/30/2025, is +191.19%.
The Serie's change in percent from it's maximum value, on 09/30/2025, to it's latest available value, on 09/30/2025, is 0.0%.